Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

JHL Biotech Settles IP Suit with Genentech, Discontinuing Development of Four Genentech Biosimilars

publication date: Sep 9, 2019

JHL Biotech announced it has settled an IP suit brought by Genentech against the company by agreeing to stop all development of Genentech biosimilar drugs and to pay Genentech's legal and investigative costs related to the IP dispute. JHL will not be required to pay any damage fees. In 2018, four former Genentech employees were indicted for a conspiracy to steal information related to four Genentech drugs and pass the information to JHL. JHL has its headquarters and R&D opertations in Hsinchu, Taiwan, while its manufacturing facility is in Wuhan, China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital